Altimmune

About

Altimmune is a therapeutics, treatment, and vaccine development company that looks to find response and prevention solutions. The company was founded by De-chu Christopher Tang in 1997, in Gaithersburg, Maryland, United States.

The company is known for their programs that deal with peptide-based therapeutics for liver diseases, peptide-conjugated immuno-stimulants for cancer, and intranasal vaccines for Anthrax and Influenza.

COVID-19 Treatments and Solutions

With the outbreak of COVID-19, Altimmune announced the development of a single-dose, intranasal vaccine against the virus which was caused by the SARS-CoV-2 virus. The vaccine design and synthesis has been advanced to animal testing and manufacturing. A Phase 2 clinical study with NasoVAX demonstrated the ability the delivery system was durable and stimulated a broad immune response against the influenza virus. They believe the same delivery system would work for the vaccine in development for COVID-19.

Timeline

August 21, 2019

Altimmune raises a $3,700,000 grant from Biomedical Advanced Research and Development Authority.

September 28, 2018

Altimmune raises a $17,000,000 private equity.

August 17, 2017

Altimmune raises a $14,700,000 private equity.

February 17, 2015

Altimmune raises a $16,000,000 private equity from HealthCap, Novartis Venture Fund, Redmont Capital and Truffle Capital.

Funding Rounds

Products

Patents

Further Resources

Title

Author

Link

Type

Date

Altimmune

jpoly4

https://altimmune.com

Web

November 15, 2019

Altimmune Completes First Development Milestone Toward a Single-Dose Intranasal COVID-19 Vaccine - Altimmune

https://ir.altimmune.com/news-releases/news-release-details/altimmune-completes-first-development-milestone-toward-single

Web

Coronavirus outbreak: Top coronavirus drugs and vaccines in development

https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/

Web

March 6, 2020

News

Title

Author

Date

Publisher

Description

Poor Results Force Biotech Firm To Halt Trials for Intranasal COVID-19 Vaccine

Vanessa Doctor, RN

June 30, 2021

BioSpace

The company said it would halt activities and focus its resources and time on liver and obesity research following "disappointing" results of its intranasal COVID-19 vaccine.

Altimmune ditches COVID-19 nasal spray vaccine, halts therapeutic enrollment after trial setbacks

Kyle LaHucik

June 29, 2021

FierceBiotech

After not-so-promising results from a phase 1 trial, Altimmune is scrapping its COVID-19 vaccine nasal spray candidate and stopping further enrollment in a COVID-19 therapeutic program. The news comes just as the Delta variant picks up steam around the world.

Altimmune Demonstrates Strong Neutralization of South African Variant in Preclinical Study of Intranasal AdCOVIDTM

BioSpace

May 26, 2021

BioSpace

Altimmune, Inc., a clinical-stage biopharmaceutical company, announced new results from a preclinical study demonstrating the ability of its AdCOVID vaccine candidate to neutralize the rapidly emerging SARS-CoV-2 B.1.351 variant of concern that originated in South Africa.

Altimmune Announces New Preclinical Data for AdCOVIDTM Demonstrating Sterilizing Immunity After a Single Intranasal Dose

BioSpace

May 10, 2021

BioSpace

Altimmune, Inc., a clinical-stage biopharmaceutical company, announced positive results from a preclinical study of AdCOVID in a SARS-CoV-2 challenge model of infection.

Intranasal COVID-19 vaccine spray could stem spread, researchers say

Aylin Woodward and Allison DeAngelis

March 5, 2021

Business Insider

A company called Altimmune is working on a nasal-spray version of a COVID-19 vaccine. The technology could stem the virus' spread better than shots.